CAR T-Cell Therapy: Pediatric Patients With Relapsed and Refractory Acute Lymphoblastic Leukemia .
Immunotherapy provides a promising treatment option for children and adolescents with refractory or relapsed acute lymphoblastic leukemia (ALL).  .



This article presents a hospital's experience with providing chimeric antigen receptor (CAR) T-cell therapy, followed by a detailed discussion of the trajectory of treatment provided for pediatric patients and their families. .



Clinical experience in delivering care to pediatric patients undergoing CAR T-cell therapy is described. Care coordination, patient and family assessment and education, and post-CAR T-cell infusion monitoring are presented.  .



Of 59 patients having been treated with CAR T-cell therapy at the authors' institution, 93% had a complete response at day 28. The 12-month relapse-free survival rate is 55%. A multidisciplinary team of skilled clinicians is recommended to support patient and family needs throughout screening, treatment, and follow-up while coordinating care with the referring oncologist.
Children's Hospital of Philadelphia.
Colleen
C
Callahan
Children's Hospital of Philadelphia.
Diane
D
Baniewicz
Children's Hospital of Philadelphia.
Beth
B
Ely
D000293:Adolescent; D064987:Cell- and Tissue-Based Therapy; D002648:Child; D002678:Chimera / Q000276:immunology*; D004509:Education, Nursing, Continuing; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy*; D011948:Receptors, Antigen, T-Cell / Q000276:immunology / Q000627:therapeutic use*; D012008:Recurrence; D013601:T-Lymphocytes / Q000276:immunology*
D011948:Receptors, Antigen, T-Cell
CAR T-cell therapy; CART-19; acute lymphoblastic leukemia; immunotherapy